Ahmed M. Salman

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Management of Anorectal Malformations at a Tertiary Hospital in Tanzania: A Retrospective Cross-Sectional Study.

Management of Anorectal Malformations at a Tertiary Hospital in Tanzania: A Retrospective Cross-Sectional Study.

Journal: Cureus

Published: July 20, 2026

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.

Journal: Wellcome open research

Published: March 19, 2026

Recent Advances, Bottlenecks, and Future Directions in Plasmodium falciparum Vaccine Development.

Recent Advances, Bottlenecks, and Future Directions in Plasmodium falciparum Vaccine Development.

Journal: Vaccines

Published: February 06, 2026

Bivalent virus-like particles expressing SPECT1 and CSP trigger pre-erythrocytic malaria immunity and protect against transgenic Plasmodium falciparum sporozoite challenge in mice.

Bivalent virus-like particles expressing SPECT1 and CSP trigger pre-erythrocytic malaria immunity and protect against transgenic Plasmodium falciparum sporozoite challenge in mice.

Journal: Frontiers in immunology

Published: January 17, 2026

Efficacy of anti-VEGF single-chain variable fragment AAV-based gene therapy in a laser-induced choroidal neovascularisation mouse model.

Efficacy of anti-VEGF single-chain variable fragment AAV-based gene therapy in a laser-induced choroidal neovascularisation mouse model.

Journal: Molecular therapy. Advances

Published: January 07, 2026

Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].

Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].

Journal: Vaccine

Published: November 16, 2025

Giant Prolactinoma Resistant to High-Dose Cabergoline in a Young Male Lost to Follow-Up.

Giant Prolactinoma Resistant to High-Dose Cabergoline in a Young Male Lost to Follow-Up.

Journal: Cureus

Published: October 27, 2025

Pre-existing retinal inflammation exacerbates gene therapy-associated uveitis in more rapidly progressive retinal degeneration.

Pre-existing retinal inflammation exacerbates gene therapy-associated uveitis in more rapidly progressive retinal degeneration.

Journal: Molecular therapy. Advances

Published: October 08, 2025

Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM.

Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM.

Journal: Vaccine

Published: August 20, 2025

Single-cell and spatial transcriptomic analyses of gene therapy-associated retinal inflammation in non-human primates.

Single-cell and spatial transcriptomic analyses of gene therapy-associated retinal inflammation in non-human primates.

Journal: Molecular therapy. Advances

Published: July 31, 2025

Subcutaneous administration of the malaria R21/Matrix M vaccine and immune complex formation with anti-circumsporozoite protein mAb 2A10 elicit protective efficacy in mice.

Subcutaneous administration of the malaria R21/Matrix M vaccine and immune complex formation with anti-circumsporozoite protein mAb 2A10 elicit protective efficacy in mice.

Journal: Frontiers in immunology

Published: July 29, 2025

Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.

Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.

Journal: Frontiers in immunology

Published: April 29, 2025

Showing 1-12 of 60

Last Updated: 09/26/2026